You are the owner of this page.
Edit Page
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Vistagen Therap. Com (NQ: VTGN )

0.8200 USD +0.0350 (+4.46%)
Official Closing Price Updated: 7:29 PM EDT, Oct 20, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 957,720
Open 0.7868
Bid (Size) 0.8200 (19)
Ask (Size) 0.8244 (10)
Prev. Close 0.7850
Today's Range 0.7400 - 0.8250
52wk Range 0.2943 - 1.490
Shares Outstanding 23,037,615
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Nasdaq Grants VistaGen 180-Day Extension to Meet Minimum Bid Price Requirement
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced that the... 
From PR Newswire
BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Research Report
From InvestorBrandNetwork

Performance

YTD
+9.33%
+9.33%
1 Month
+28.75%
+28.75%
3 Month
+10.81%
+10.81%
6 Month
+95.24%
+95.24%
1 Year
-41.84%
-41.84%

More News

Read More
BioMedNewsBreaks – Why VistaGen Therapeutics (NASDAQ: VTGN) Is ‘One to Watch’
From InvestorBrandNetwork
VistaGen Reports Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid
From PR Newswire
VistaGen Therapeutics to Present at the LD Micro 500 Virtual Conference
From PR Newswire
VistaGen Therapeutics Inc. (NASDAQ: VTGN) is “One to Watch”
From InvestorBrandNetwork
BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses ‘Sea of Change’ to Future of Anxiety Treatment
From InvestorBrandNetwork
BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Addresses ‘Multi-Pronged Approach’ to Growing Problem of Workplace Stress and Anxiety
From InvestorBrandNetwork
VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress
From PR Newswire
NetworkNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses PH94B Drug Candidate in Applied Clinical Trials Publication
From InvestorBrandNetwork
VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.